董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Susannah Gray | 女 | Director | 66 | 未披露 | 未持股 | 2026-04-28 |
| John Orwin | 男 | Director | 61 | 37.02万美元 | 3.45 | 2026-04-28 |
| Daniel Faga | 男 | Chief Executive Officer, Director and President | 46 | 613.39万美元 | 69.92 | 2026-04-28 |
| John Orwin | 男 | Director | 61 | 未披露 | 未持股 | 2026-04-28 |
| Daniel Faga | 男 | Chief Executive Officer, Director and President | 46 | 未披露 | 未持股 | 2026-04-28 |
| Hollings Renton | 男 | Director | 79 | 32.02万美元 | 12.39 | 2026-04-28 |
| John P. Schmid | 男 | Director | 63 | 33.70万美元 | 14.81 | 2026-04-28 |
| Oleg Nodelman | 男 | Director | 49 | 未披露 | 788.01 | 2026-04-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel Faga | 男 | Chief Executive Officer, Director and President | 46 | 613.39万美元 | 69.92 | 2026-04-28 |
| Daniel Faga | 男 | Chief Executive Officer, Director and President | 46 | 未披露 | 未持股 | 2026-04-28 |
董事简历
中英对照 | 中文 | 英文- Susannah Gray
-
Susannah Gray自2020年7月起担任我们的董事会成员。Gray女士曾于2005年至2019年担任Royalty Pharma Management，LLC财务和战略执行Vice President，该公司是药品特许权使用费的购买者和整个生物制药行业的供资者，并担任其他各种类似职务。在加入Royalty Pharma之前，Gray女士从2002年到2004年担任CIBS世界市场高收益集团梦百合部门的董事总经理和高级分析师，此前还在摩根大通证券公司的前身美林证券公司和大通证券公司担任过类似职务。Gray女士目前在Susan G.Komen的董事会任职，并在卫斯理大学（Wesleyan University）的董事会任职。Gray女士于1982年在卫斯理大学（Wesleyan University）获得文学学士学位，并于1990年在哥伦比亚大学（Columbia University）获得工商管理硕士学位。
Susannah Gray has served as a member of board of directors since July 2020. Ms. Gray served as the Executive Vice President of Finance and Strategy of Royalty Pharma Management, LLC, a buyer of pharmaceutical royalties and a funder across the biopharmaceutical industry, and in various other similar roles from 2005 until 2019. Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector of CIBS World Market's high yield group from 2002 to 2004 and also previously served in similar roles at Merrill Lynch and Chase Securities, Inc. predecessor of JP Morgan Securities, Inc.. Ms. Gray currently serves on the board of directors of Susan G. Komen and serves on the Board of Trustees of Wesleyan University. Ms. Gray received a B.A. from Wesleyan University in 1982 and an M.B.A. from Columbia University in 1990. - Susannah Gray自2020年7月起担任我们的董事会成员。Gray女士曾于2005年至2019年担任Royalty Pharma Management，LLC财务和战略执行Vice President，该公司是药品特许权使用费的购买者和整个生物制药行业的供资者，并担任其他各种类似职务。在加入Royalty Pharma之前，Gray女士从2002年到2004年担任CIBS世界市场高收益集团梦百合部门的董事总经理和高级分析师，此前还在摩根大通证券公司的前身美林证券公司和大通证券公司担任过类似职务。Gray女士目前在Susan G.Komen的董事会任职，并在卫斯理大学（Wesleyan University）的董事会任职。Gray女士于1982年在卫斯理大学（Wesleyan University）获得文学学士学位，并于1990年在哥伦比亚大学（Columbia University）获得工商管理硕士学位。
- Susannah Gray has served as a member of board of directors since July 2020. Ms. Gray served as the Executive Vice President of Finance and Strategy of Royalty Pharma Management, LLC, a buyer of pharmaceutical royalties and a funder across the biopharmaceutical industry, and in various other similar roles from 2005 until 2019. Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector of CIBS World Market's high yield group from 2002 to 2004 and also previously served in similar roles at Merrill Lynch and Chase Securities, Inc. predecessor of JP Morgan Securities, Inc.. Ms. Gray currently serves on the board of directors of Susan G. Komen and serves on the Board of Trustees of Wesleyan University. Ms. Gray received a B.A. from Wesleyan University in 1982 and an M.B.A. from Columbia University in 1990.
- John Orwin
-
John Orwin，自2022年9月起担任Cargo Therapeutics，Inc.董事会主席。自2018年4月起，奥文先生担任上市生物制药公司Atreca, Inc.的总裁兼首席执行官。2013年至2017年，Orwin先生担任Relypsa, Inc.的总裁兼首席执行官，该公司是一家生物制药公司，于2016年被Galenica AG收购。在此之前，2010年至2011年，Orwin先生担任上市生物技术公司Affymax, Inc.的总裁兼首席执行官。2005年至2010年，Orwin先生担任基因泰克生物肿瘤业务部门副总裁，后来又担任高级副总裁。Genentech是一家私有生物技术公司，也是罗氏集团的成员。Orwin先生目前担任Atreca, Inc.、Travere Therapeutics公司和Seagen公司的董事会成员。Orwin先生以前曾担任Affymax公司的董事会成员。公司、Array BioPharma公司、Relypsa公司和NeurogesX公司。Orwin先生在罗格斯大学获得经济学学士学位，在纽约大学Leonard M. Stern商学院获得工商管理硕士学位。
John Orwin serves as Chairman of the Board, effective prior to the completion of the Spin Off. He has served as a member and Chairman of the AnaptysBio, Inc. Board since September 2023. Mr. Orwin has been a venture partner at Samsara BioCapital, L.P., a venture capital group, since 2024, and currently serves as the chair of the board of directors of Nested Therapeutics, Inc., a privately held company, serves on the board of directors of Ambrosia Biosciences, Inc., a privately held company, and as executive chairman of the board of directors of Agni Bio, Inc., a privately held company. Mr. Orwin served as the President and Chief Executive Officer of Atreca, Inc. from April 2018 to June 2024. He also has served as a member of the board of directors of CARGO Therapeutics, Inc. since August 2022, and Travere Therapeutics, Inc. since March 2017. He previously served as a member of the boards of directors of Seagen, Inc. from January 2014 until its acquisition by Pfizer Inc. in December 2023 and Array BioPharma, Inc. from November 2012 to July 2019. Mr. Orwin received a B.A. in Economics from Rutgers, The State University of New Jersey and an M.B.A. from New York University. - John Orwin，自2022年9月起担任Cargo Therapeutics，Inc.董事会主席。自2018年4月起，奥文先生担任上市生物制药公司Atreca, Inc.的总裁兼首席执行官。2013年至2017年，Orwin先生担任Relypsa, Inc.的总裁兼首席执行官，该公司是一家生物制药公司，于2016年被Galenica AG收购。在此之前，2010年至2011年，Orwin先生担任上市生物技术公司Affymax, Inc.的总裁兼首席执行官。2005年至2010年，Orwin先生担任基因泰克生物肿瘤业务部门副总裁，后来又担任高级副总裁。Genentech是一家私有生物技术公司，也是罗氏集团的成员。Orwin先生目前担任Atreca, Inc.、Travere Therapeutics公司和Seagen公司的董事会成员。Orwin先生以前曾担任Affymax公司的董事会成员。公司、Array BioPharma公司、Relypsa公司和NeurogesX公司。Orwin先生在罗格斯大学获得经济学学士学位，在纽约大学Leonard M. Stern商学院获得工商管理硕士学位。
- John Orwin serves as Chairman of the Board, effective prior to the completion of the Spin Off. He has served as a member and Chairman of the AnaptysBio, Inc. Board since September 2023. Mr. Orwin has been a venture partner at Samsara BioCapital, L.P., a venture capital group, since 2024, and currently serves as the chair of the board of directors of Nested Therapeutics, Inc., a privately held company, serves on the board of directors of Ambrosia Biosciences, Inc., a privately held company, and as executive chairman of the board of directors of Agni Bio, Inc., a privately held company. Mr. Orwin served as the President and Chief Executive Officer of Atreca, Inc. from April 2018 to June 2024. He also has served as a member of the board of directors of CARGO Therapeutics, Inc. since August 2022, and Travere Therapeutics, Inc. since March 2017. He previously served as a member of the boards of directors of Seagen, Inc. from January 2014 until its acquisition by Pfizer Inc. in December 2023 and Array BioPharma, Inc. from November 2012 to July 2019. Mr. Orwin received a B.A. in Economics from Rutgers, The State University of New Jersey and an M.B.A. from New York University.
- Daniel Faga
-
Daniel Faga于2022年3月至2023年8月期间担任AnaptysBio，Inc.的临时总裁兼首席执行官。2020年1月至2021年11月，Faga先生在Mirati Therapeutics担任首席运营官，负责领导公司的公司战略、财务、法律和其他BINCE运营。在加入Mirati之前，Faga先生于2016年5月至2019年12月期间担任星火治疗，Inc.的首席BINCE官，负责领导公司的公司战略、产品组合和新产品规划、患者倡导、BINCE开发、联盟管理、资产和项目管理以及企业传播职能。从2009年7月到2016年4月，Faga先生担任投资银行和咨询公司CenterView Partners的董事总经理，并担任CenterView的医疗保健咨询业务的创始成员。在加入CenterView之前，Faga先生曾在美林证券的医疗保健投资银行集团任职，并在PRTM担任生命科学实践部门的管理顾问。法加先生获得了康奈尔大学的工程学学士学位和宾夕法尼亚大学沃顿商学院的医疗保健管理硕士学位。
Daniel Faga serves as First Tracks Biotherapeutics, Inc. President, Chief Executive Officer and a member of First Tracks Biotherapeutics, Inc. Board effective prior to the completion of the Spin Off. He currently serves as President and Chief Executive Officer and a member of the AnaptysBio, Inc. Board. Mr. Faga previously served as the Interim President and Chief Executive Officer of AnaptysBio, Inc. from March 2022 to August 2023. From January 2020 to November 2021, Mr. Faga served as Chief Operating Officer at Mirati Therapeutics, responsible for leading the company's corporate strategy, finance, legal and other business operations. Prior to joining Mirati, Mr. Faga served as the Chief Business Officer for Spark Therapeutics, Inc. from May 2016 through December 2019, where he was responsible for leading the company's corporate strategy, portfolio and new product planning, patient advocacy, business development, alliance management, asset & program management and corporate communications functions. From July 2009 until April 2016, Mr. Faga was a Managing Director at Centerview Partners, an investment banking and advisory firm, where he served as a founding member of Centerview's healthcare advisory practice. Prior to Centerview, Mr. Faga worked at Merrill Lynch in its healthcare investment banking group and as a management consultant in the Life Sciences Practice at PRTM. Mr. Faga earned a B.S. in Engineering from Cornell University and an M.B.A. in Health Care Management from The Wharton School at the University of Pennsylvania. - Daniel Faga于2022年3月至2023年8月期间担任AnaptysBio，Inc.的临时总裁兼首席执行官。2020年1月至2021年11月，Faga先生在Mirati Therapeutics担任首席运营官，负责领导公司的公司战略、财务、法律和其他BINCE运营。在加入Mirati之前，Faga先生于2016年5月至2019年12月期间担任星火治疗，Inc.的首席BINCE官，负责领导公司的公司战略、产品组合和新产品规划、患者倡导、BINCE开发、联盟管理、资产和项目管理以及企业传播职能。从2009年7月到2016年4月，Faga先生担任投资银行和咨询公司CenterView Partners的董事总经理，并担任CenterView的医疗保健咨询业务的创始成员。在加入CenterView之前，Faga先生曾在美林证券的医疗保健投资银行集团任职，并在PRTM担任生命科学实践部门的管理顾问。法加先生获得了康奈尔大学的工程学学士学位和宾夕法尼亚大学沃顿商学院的医疗保健管理硕士学位。
- Daniel Faga serves as First Tracks Biotherapeutics, Inc. President, Chief Executive Officer and a member of First Tracks Biotherapeutics, Inc. Board effective prior to the completion of the Spin Off. He currently serves as President and Chief Executive Officer and a member of the AnaptysBio, Inc. Board. Mr. Faga previously served as the Interim President and Chief Executive Officer of AnaptysBio, Inc. from March 2022 to August 2023. From January 2020 to November 2021, Mr. Faga served as Chief Operating Officer at Mirati Therapeutics, responsible for leading the company's corporate strategy, finance, legal and other business operations. Prior to joining Mirati, Mr. Faga served as the Chief Business Officer for Spark Therapeutics, Inc. from May 2016 through December 2019, where he was responsible for leading the company's corporate strategy, portfolio and new product planning, patient advocacy, business development, alliance management, asset & program management and corporate communications functions. From July 2009 until April 2016, Mr. Faga was a Managing Director at Centerview Partners, an investment banking and advisory firm, where he served as a founding member of Centerview's healthcare advisory practice. Prior to Centerview, Mr. Faga worked at Merrill Lynch in its healthcare investment banking group and as a management consultant in the Life Sciences Practice at PRTM. Mr. Faga earned a B.S. in Engineering from Cornell University and an M.B.A. in Health Care Management from The Wharton School at the University of Pennsylvania.
- John Orwin
-
约翰·奥文自2023年9月起担任董事会成员和董事长。自2024年以来，Orwin先生一直是风险投资集团Samsara BioCapital，L.P.的风险合伙人，目前担任私营公司Nested Therapeutics，Inc.的董事会主席，担任私营公司Ambrosia Biosciences，Inc.的董事会成员，并担任私营公司Agni Bio，Inc.董事会的执行主席。Orwin先生于2018年4月至2024年6月期间担任Atreca公司总裁兼首席执行官。他还自2022年8月起担任CARGO Therapeutics，Inc.的董事会成员，自2017年3月起担任Travere Therapeutics，Inc.的董事会成员。此前，他于2014年1月起担任Seagen，Inc.的董事会成员，直至2023年12月被辉瑞收购，并于2012年11月至2019年7月被Array BioPharma，Inc.收购。Orwin先生获得了Rutgers、新泽西州立大学的经济学学士学位和纽约大学的工商管理硕士学位。AnaptysBio, Inc.董事会认为，Orwin先生丰富的行业经验和在多家生物制药公司担任的高管职务使其有资格在AnaptysBio, Inc.董事会任职。
John Orwin has served as a member and Chairman of Board since September 2023. Mr. Orwin has been a venture partner at Samsara BioCapital, L.P., a venture capital group, since 2024, and currently serves as the chair of the board of directors of Nested Therapeutics, Inc., a privately held company, serves on the board of directors of Ambrosia Biosciences, Inc., a privately held company, and as executive chairman of the board of directors of Agni Bio, Inc., a privately held company. Mr. Orwin served as the President and Chief Executive Officer of Atreca, Inc. from April 2018 to June 2024. He also has served as a member of the board of directors of CARGO Therapeutics, Inc. since August 2022, and Travere Therapeutics, Inc. since March 2017. He previously served as a member of the boards of directors of Seagen, Inc. from January 2014 until its acquisition by Pfizer Inc. in December 2023 and Array BioPharma, Inc. from November 2012 to July 2019. Mr. Orwin received a B.A. in Economics from Rutgers, The State University of New Jersey and an M.B.A. from New York University. Anaptysbio, Inc.'s Board believes that Mr. Orwin's extensive industry experience and executive positions at multiple biopharmaceutical companies qualify him to serve on Anaptysbio, Inc.'s Board. - 约翰·奥文自2023年9月起担任董事会成员和董事长。自2024年以来，Orwin先生一直是风险投资集团Samsara BioCapital，L.P.的风险合伙人，目前担任私营公司Nested Therapeutics，Inc.的董事会主席，担任私营公司Ambrosia Biosciences，Inc.的董事会成员，并担任私营公司Agni Bio，Inc.董事会的执行主席。Orwin先生于2018年4月至2024年6月期间担任Atreca公司总裁兼首席执行官。他还自2022年8月起担任CARGO Therapeutics，Inc.的董事会成员，自2017年3月起担任Travere Therapeutics，Inc.的董事会成员。此前，他于2014年1月起担任Seagen，Inc.的董事会成员，直至2023年12月被辉瑞收购，并于2012年11月至2019年7月被Array BioPharma，Inc.收购。Orwin先生获得了Rutgers、新泽西州立大学的经济学学士学位和纽约大学的工商管理硕士学位。AnaptysBio, Inc.董事会认为，Orwin先生丰富的行业经验和在多家生物制药公司担任的高管职务使其有资格在AnaptysBio, Inc.董事会任职。
- John Orwin has served as a member and Chairman of Board since September 2023. Mr. Orwin has been a venture partner at Samsara BioCapital, L.P., a venture capital group, since 2024, and currently serves as the chair of the board of directors of Nested Therapeutics, Inc., a privately held company, serves on the board of directors of Ambrosia Biosciences, Inc., a privately held company, and as executive chairman of the board of directors of Agni Bio, Inc., a privately held company. Mr. Orwin served as the President and Chief Executive Officer of Atreca, Inc. from April 2018 to June 2024. He also has served as a member of the board of directors of CARGO Therapeutics, Inc. since August 2022, and Travere Therapeutics, Inc. since March 2017. He previously served as a member of the boards of directors of Seagen, Inc. from January 2014 until its acquisition by Pfizer Inc. in December 2023 and Array BioPharma, Inc. from November 2012 to July 2019. Mr. Orwin received a B.A. in Economics from Rutgers, The State University of New Jersey and an M.B.A. from New York University. Anaptysbio, Inc.'s Board believes that Mr. Orwin's extensive industry experience and executive positions at multiple biopharmaceutical companies qualify him to serve on Anaptysbio, Inc.'s Board.
- Daniel Faga
-
Daniel Faga自2021年11月起担任董事会成员，并自2023年8月起担任AnaptysBio, Inc.总裁兼首席执行官。Faga先生此前曾于2022年3月至2023年8月担任AnaptysBio, Inc.的临时总裁兼首席执行官。2020年1月至2021年11月，Faga先生在Mirati Therapeutics担任首席运营官，负责领导公司的公司战略、财务、法律和其他业务运营。在加入Mirati Therapeutics之前，Faga先生于2016年5月至2019年12月期间担任星火治疗，Inc.的首席商务官，负责领导公司的公司战略、产品组合和新产品规划、患者宣传、业务发展、联盟管理、资产和项目管理以及企业传播职能。从2009年7月到2016年4月，Faga先生在投资银行和咨询公司CenterView Partners担任董事总经理，并担任CenterView的医疗保健咨询业务的创始成员。在加入CenterView之前，Faga先生曾在美林证券的医疗保健投资银行集团任职，并在PRTM担任生命科学实践部门的管理顾问。法加先生获得了康奈尔大学的工程学学士学位和宾夕法尼亚大学沃顿商学院的医疗保健管理硕士学位。AnaptysBio, Inc.董事会认为，Faga先生丰富的行业经验和高管经验为其提供了在AnaptysBio, Inc.董事会任职的资格和技能。
Daniel Faga has served as a member of Board since November 2021, and has served as Anaptysbio, Inc.'s President and Chief Executive Officer since August 2023. Mr. Faga previously served as Anaptysbio, Inc.'s Interim President and Chief Executive Officer from March 2022 to August 2023. From January 2020 to November 2021, Mr. Faga served as Chief Operating Officer at Mirati Therapeutics, responsible for leading the company's corporate strategy, finance, legal and other business operations. Prior to joining Mirati Therapeutics, Mr. Faga served as the Chief Business Officer for Spark Therapeutics, Inc. from May 2016 through December 2019, where he was responsible for leading the company's corporate strategy, portfolio and new product planning, patient advocacy, business development, alliance management, asset & program management and corporate communications functions. From July 2009 until April 2016, Mr. Faga was a Managing Director at Centerview Partners, an investment banking and advisory firm, where he served as a founding member of Centerview's healthcare advisory practice. Prior to Centerview, Mr. Faga worked at Merrill Lynch in its healthcare investment banking group and as a management consultant in the Life Sciences Practice at PRTM. Mr. Faga earned a B.S. in Engineering from Cornell University and an M.B.A. in Health Care Management from The Wharton School at the University of Pennsylvania. Anaptysbio, Inc.'s Board believes that Mr. Faga's extensive industry experience and executive experience provides him with the qualifications and skills to serve on Anaptysbio, Inc.'s Board. - Daniel Faga自2021年11月起担任董事会成员，并自2023年8月起担任AnaptysBio, Inc.总裁兼首席执行官。Faga先生此前曾于2022年3月至2023年8月担任AnaptysBio, Inc.的临时总裁兼首席执行官。2020年1月至2021年11月，Faga先生在Mirati Therapeutics担任首席运营官，负责领导公司的公司战略、财务、法律和其他业务运营。在加入Mirati Therapeutics之前，Faga先生于2016年5月至2019年12月期间担任星火治疗，Inc.的首席商务官，负责领导公司的公司战略、产品组合和新产品规划、患者宣传、业务发展、联盟管理、资产和项目管理以及企业传播职能。从2009年7月到2016年4月，Faga先生在投资银行和咨询公司CenterView Partners担任董事总经理，并担任CenterView的医疗保健咨询业务的创始成员。在加入CenterView之前，Faga先生曾在美林证券的医疗保健投资银行集团任职，并在PRTM担任生命科学实践部门的管理顾问。法加先生获得了康奈尔大学的工程学学士学位和宾夕法尼亚大学沃顿商学院的医疗保健管理硕士学位。AnaptysBio, Inc.董事会认为，Faga先生丰富的行业经验和高管经验为其提供了在AnaptysBio, Inc.董事会任职的资格和技能。
- Daniel Faga has served as a member of Board since November 2021, and has served as Anaptysbio, Inc.'s President and Chief Executive Officer since August 2023. Mr. Faga previously served as Anaptysbio, Inc.'s Interim President and Chief Executive Officer from March 2022 to August 2023. From January 2020 to November 2021, Mr. Faga served as Chief Operating Officer at Mirati Therapeutics, responsible for leading the company's corporate strategy, finance, legal and other business operations. Prior to joining Mirati Therapeutics, Mr. Faga served as the Chief Business Officer for Spark Therapeutics, Inc. from May 2016 through December 2019, where he was responsible for leading the company's corporate strategy, portfolio and new product planning, patient advocacy, business development, alliance management, asset & program management and corporate communications functions. From July 2009 until April 2016, Mr. Faga was a Managing Director at Centerview Partners, an investment banking and advisory firm, where he served as a founding member of Centerview's healthcare advisory practice. Prior to Centerview, Mr. Faga worked at Merrill Lynch in its healthcare investment banking group and as a management consultant in the Life Sciences Practice at PRTM. Mr. Faga earned a B.S. in Engineering from Cornell University and an M.B.A. in Health Care Management from The Wharton School at the University of Pennsylvania. Anaptysbio, Inc.'s Board believes that Mr. Faga's extensive industry experience and executive experience provides him with the qualifications and skills to serve on Anaptysbio, Inc.'s Board.
- Hollings Renton
-
Hollings Renton，自2017年2月起担任Zymeworks Inc.董事会成员。Renton先生于1993年3月至2008年3月担任Onyx Pharmaceuticals，Inc.首席执行官兼总裁，并于2000年6月至2008年3月担任Onyx董事会主席。Onyx于2013年被安进以104亿美元的价格收购。在加入Onyx之前，Renton先生于1991年12月至1993年12月担任制药公司Chiron Corporation的总裁兼首席运营官。Renton先生于1983年在Cetus Corporation担任过多种行政职务，包括1990年至1991年担任总裁、1987年至1990年担任首席运营官以及1983年至1987年担任首席财务官，之后该公司于1991年被Chiron收购。Renton先生自2015年6月起担任AnaptysBio公司董事会成员。此前，Renton先生曾在其他四家生物制药公司的董事会任职，即波尔图制药 Inc.，他还曾担任该公司的董事会主席（2010年3月至2020年7月）、KYTHERA Biopharmaceuticals，Inc.（2014年12月至2015年10月）、Affymax, Inc.（2009年6月至2014年11月）和Rigel Pharmaceuticals, Inc.（2004年1月至2014年3月）。Renton此前还曾在2000年3月至2016年11月期间担任分子诊断公司Cepheid Inc.的董事会成员。Renton先生获得了密西根大学的工商管理硕士学位和科罗拉多州立大学的数学学士学位。
Hollings Renton has served as a member of Board since June 2015. Mr. Renton previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from 1993 to 2008 and as the chairperson of its board of directors from 2000 to 2008. Before joining Onyx Pharmaceuticals, Mr. Renton served as the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, from 1991 to 1993, following its acquisition of Cetus Corporation. Mr. Renton served as the President of Cetus Corporation from 1990 to 1991, as Chief Operating Officer from 1987 to 1990, and as Chief Financial Officer from 1983 to 1987. Mr. Renton previously served on the board of directors of Zymeworks, Inc., a publicly traded company from 2017 to 2024 and Portola Pharmaceuticals, Inc., a publicly traded company, from March 2010 to June 2020. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University. - Hollings Renton，自2017年2月起担任Zymeworks Inc.董事会成员。Renton先生于1993年3月至2008年3月担任Onyx Pharmaceuticals，Inc.首席执行官兼总裁，并于2000年6月至2008年3月担任Onyx董事会主席。Onyx于2013年被安进以104亿美元的价格收购。在加入Onyx之前，Renton先生于1991年12月至1993年12月担任制药公司Chiron Corporation的总裁兼首席运营官。Renton先生于1983年在Cetus Corporation担任过多种行政职务，包括1990年至1991年担任总裁、1987年至1990年担任首席运营官以及1983年至1987年担任首席财务官，之后该公司于1991年被Chiron收购。Renton先生自2015年6月起担任AnaptysBio公司董事会成员。此前，Renton先生曾在其他四家生物制药公司的董事会任职，即波尔图制药 Inc.，他还曾担任该公司的董事会主席（2010年3月至2020年7月）、KYTHERA Biopharmaceuticals，Inc.（2014年12月至2015年10月）、Affymax, Inc.（2009年6月至2014年11月）和Rigel Pharmaceuticals, Inc.（2004年1月至2014年3月）。Renton此前还曾在2000年3月至2016年11月期间担任分子诊断公司Cepheid Inc.的董事会成员。Renton先生获得了密西根大学的工商管理硕士学位和科罗拉多州立大学的数学学士学位。
- Hollings Renton has served as a member of Board since June 2015. Mr. Renton previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from 1993 to 2008 and as the chairperson of its board of directors from 2000 to 2008. Before joining Onyx Pharmaceuticals, Mr. Renton served as the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, from 1991 to 1993, following its acquisition of Cetus Corporation. Mr. Renton served as the President of Cetus Corporation from 1990 to 1991, as Chief Operating Officer from 1987 to 1990, and as Chief Financial Officer from 1983 to 1987. Mr. Renton previously served on the board of directors of Zymeworks, Inc., a publicly traded company from 2017 to 2024 and Portola Pharmaceuticals, Inc., a publicly traded company, from March 2010 to June 2020. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University.
- John P. Schmid
-
John P. Schmid，自2015年6月起担任董事；2013年9月至2015年6月间担任Auspex Pharmaceuticals, Inc.的首席财务官。在加入Auspex Pharmaceuticals之前，他联合成立了Trius Therapeutics, Inc.（上市的生物制药公司），并于2004年6月至2013年9月与Cubist Pharmaceuticals, Inc.合并前担任首席财务官。在加入Trius Therapeutics, Inc.之前，他于1998年至2003年和1995年至1998年间分别担任GeneFormatics, Inc.（私营生物技术公司）和Endonetics, Inc.（私营医疗设备公司）的首席财务官。他目前是Neos Therapeutics, Inc.（制药公司）的董事，也是Speak, Inc.（演说家办事处）的董事长，他于1989年联合成立该公司。他获得了the University of San Diego的工商管理硕士学位，以及Wesleyan University的学士学位。
John P. Schmid serves as a member of First Tracks Biotherapeutics, Inc. Board, effective prior to the completion of the Spin Off. Mr. Schmid has served as a member of the AnaptysBio, Inc. Board since June 2015. Mr. Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 to June 2015. Before joining Auspex Pharmaceuticals, Mr. Schmid co founded Trius Therapeutics, a publicly traded biopharmaceutical company, where he served as the Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc., in September 2013. Before he joined Trius Therapeutics, Mr. Schmid served as the Chief Financial Officer at GeneFormatics, Inc., a private biotechnology company, from 1998 to 2003, and at Endonetics, a private medical device company, from 1995 to 1998. Mr. Schmid currently serves as a member of the board of directors of the publicly traded company Design Therapeutics Inc., a pharmaceutical company, and Bright Peak Therapeutics, a private biotechnology company. In the last five years, Mr. Schmid has previously served on the boards of directors of Helix Acquisition Corp. and Helix Acquisition Corp. II, both special purpose acquisition companies, Neos Therapeutics, Poseida Therapeutics, Inc., and Xeris Pharmaceuticals, all pharmaceutical companies. Mr. Schmid received his M.B.A. from the University of San Diego and his B.A. from Wesleyan University. - John P. Schmid，自2015年6月起担任董事；2013年9月至2015年6月间担任Auspex Pharmaceuticals, Inc.的首席财务官。在加入Auspex Pharmaceuticals之前，他联合成立了Trius Therapeutics, Inc.（上市的生物制药公司），并于2004年6月至2013年9月与Cubist Pharmaceuticals, Inc.合并前担任首席财务官。在加入Trius Therapeutics, Inc.之前，他于1998年至2003年和1995年至1998年间分别担任GeneFormatics, Inc.（私营生物技术公司）和Endonetics, Inc.（私营医疗设备公司）的首席财务官。他目前是Neos Therapeutics, Inc.（制药公司）的董事，也是Speak, Inc.（演说家办事处）的董事长，他于1989年联合成立该公司。他获得了the University of San Diego的工商管理硕士学位，以及Wesleyan University的学士学位。
- John P. Schmid serves as a member of First Tracks Biotherapeutics, Inc. Board, effective prior to the completion of the Spin Off. Mr. Schmid has served as a member of the AnaptysBio, Inc. Board since June 2015. Mr. Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 to June 2015. Before joining Auspex Pharmaceuticals, Mr. Schmid co founded Trius Therapeutics, a publicly traded biopharmaceutical company, where he served as the Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc., in September 2013. Before he joined Trius Therapeutics, Mr. Schmid served as the Chief Financial Officer at GeneFormatics, Inc., a private biotechnology company, from 1998 to 2003, and at Endonetics, a private medical device company, from 1995 to 1998. Mr. Schmid currently serves as a member of the board of directors of the publicly traded company Design Therapeutics Inc., a pharmaceutical company, and Bright Peak Therapeutics, a private biotechnology company. In the last five years, Mr. Schmid has previously served on the boards of directors of Helix Acquisition Corp. and Helix Acquisition Corp. II, both special purpose acquisition companies, Neos Therapeutics, Poseida Therapeutics, Inc., and Xeris Pharmaceuticals, all pharmaceutical companies. Mr. Schmid received his M.B.A. from the University of San Diego and his B.A. from Wesleyan University.
- Oleg Nodelman
-
Oleg Nodelman，2013年11月11日，被任命为本公司董事会成员。他是EcoR1 Capital的创始人，并从2012年10月起担任总经理，这是一家位于旧金山的价值主导型的保健行业私募投资基金。创办EcoR1 Capital之前，2001-2012，他担任 BVF Partners L.P.的投资组合经理，这是美国最古老的专业的生物技术行业对冲基金。加入BVF之前，他是Mercer Management Consulting（现Oliver Wyman）的一名顾问，这是一家专注于战略、运营、风险管理、机构变革及领导力开发的咨询公司。他现为Addex Therapeutics的董事会成员，这是一家临床阶段的生物制药公司，在瑞士证券交易所上市；也是Gladstone Institute的总裁委员会的成员。他获得了Georgetown University的科技方向的涉外服务学士学位。丰富的管理咨询经验、生物技术公司的投资经验、其它上市公司的董事任职经验，足以使他胜任本公司的董事会职务。
Oleg Nodelman has served as a member of Aktis Oncology, Inc.'s board of directors since February 2021. Since October 2012, Mr. Nodelman has served as the Founder and Portfolio Manager of EcoR1 Capital, LLC, a biotechnology focused investment advisory firm which invests in companies in all stages of research and development. From 2001 to 2012, he held various roles including Portfolio Manager at BVF Partners. Mr. Nodelman has served as a director of the biotechnology companies, AnaptysBio, Inc. (Nasdaq: ANAB) since April 2021, Galapagos NV (Nasdaq: GLPG) since October 2024 and Zymeworks Inc. (Nasdaq: ZYME) since February 2025. Previously, Mr. Nodelman served as a director of the biotechnology companies Nuvation Biosciences, Inc. (Nasdaq: NUVB) from February 2021 to December 2023 and Prothena Corporation plc from December 2019 to December 2024. Mr. Nodelman also served as a director of Panacea Acquisition Corp. II, a blank check company, from April 2020 to February 2021. Mr. Nodelman earned his BS in Foreign Service with a concentration in Science and Technology from Georgetown University. - Oleg Nodelman，2013年11月11日，被任命为本公司董事会成员。他是EcoR1 Capital的创始人，并从2012年10月起担任总经理，这是一家位于旧金山的价值主导型的保健行业私募投资基金。创办EcoR1 Capital之前，2001-2012，他担任 BVF Partners L.P.的投资组合经理，这是美国最古老的专业的生物技术行业对冲基金。加入BVF之前，他是Mercer Management Consulting（现Oliver Wyman）的一名顾问，这是一家专注于战略、运营、风险管理、机构变革及领导力开发的咨询公司。他现为Addex Therapeutics的董事会成员，这是一家临床阶段的生物制药公司，在瑞士证券交易所上市；也是Gladstone Institute的总裁委员会的成员。他获得了Georgetown University的科技方向的涉外服务学士学位。丰富的管理咨询经验、生物技术公司的投资经验、其它上市公司的董事任职经验，足以使他胜任本公司的董事会职务。
- Oleg Nodelman has served as a member of Aktis Oncology, Inc.'s board of directors since February 2021. Since October 2012, Mr. Nodelman has served as the Founder and Portfolio Manager of EcoR1 Capital, LLC, a biotechnology focused investment advisory firm which invests in companies in all stages of research and development. From 2001 to 2012, he held various roles including Portfolio Manager at BVF Partners. Mr. Nodelman has served as a director of the biotechnology companies, AnaptysBio, Inc. (Nasdaq: ANAB) since April 2021, Galapagos NV (Nasdaq: GLPG) since October 2024 and Zymeworks Inc. (Nasdaq: ZYME) since February 2025. Previously, Mr. Nodelman served as a director of the biotechnology companies Nuvation Biosciences, Inc. (Nasdaq: NUVB) from February 2021 to December 2023 and Prothena Corporation plc from December 2019 to December 2024. Mr. Nodelman also served as a director of Panacea Acquisition Corp. II, a blank check company, from April 2020 to February 2021. Mr. Nodelman earned his BS in Foreign Service with a concentration in Science and Technology from Georgetown University.
高管简历
中英对照 | 中文 | 英文- Daniel Faga
Daniel Faga于2022年3月至2023年8月期间担任AnaptysBio，Inc.的临时总裁兼首席执行官。2020年1月至2021年11月，Faga先生在Mirati Therapeutics担任首席运营官，负责领导公司的公司战略、财务、法律和其他BINCE运营。在加入Mirati之前，Faga先生于2016年5月至2019年12月期间担任星火治疗，Inc.的首席BINCE官，负责领导公司的公司战略、产品组合和新产品规划、患者倡导、BINCE开发、联盟管理、资产和项目管理以及企业传播职能。从2009年7月到2016年4月，Faga先生担任投资银行和咨询公司CenterView Partners的董事总经理，并担任CenterView的医疗保健咨询业务的创始成员。在加入CenterView之前，Faga先生曾在美林证券的医疗保健投资银行集团任职，并在PRTM担任生命科学实践部门的管理顾问。法加先生获得了康奈尔大学的工程学学士学位和宾夕法尼亚大学沃顿商学院的医疗保健管理硕士学位。
Daniel Faga serves as First Tracks Biotherapeutics, Inc. President, Chief Executive Officer and a member of First Tracks Biotherapeutics, Inc. Board effective prior to the completion of the Spin Off. He currently serves as President and Chief Executive Officer and a member of the AnaptysBio, Inc. Board. Mr. Faga previously served as the Interim President and Chief Executive Officer of AnaptysBio, Inc. from March 2022 to August 2023. From January 2020 to November 2021, Mr. Faga served as Chief Operating Officer at Mirati Therapeutics, responsible for leading the company's corporate strategy, finance, legal and other business operations. Prior to joining Mirati, Mr. Faga served as the Chief Business Officer for Spark Therapeutics, Inc. from May 2016 through December 2019, where he was responsible for leading the company's corporate strategy, portfolio and new product planning, patient advocacy, business development, alliance management, asset & program management and corporate communications functions. From July 2009 until April 2016, Mr. Faga was a Managing Director at Centerview Partners, an investment banking and advisory firm, where he served as a founding member of Centerview's healthcare advisory practice. Prior to Centerview, Mr. Faga worked at Merrill Lynch in its healthcare investment banking group and as a management consultant in the Life Sciences Practice at PRTM. Mr. Faga earned a B.S. in Engineering from Cornell University and an M.B.A. in Health Care Management from The Wharton School at the University of Pennsylvania.- Daniel Faga于2022年3月至2023年8月期间担任AnaptysBio，Inc.的临时总裁兼首席执行官。2020年1月至2021年11月，Faga先生在Mirati Therapeutics担任首席运营官，负责领导公司的公司战略、财务、法律和其他BINCE运营。在加入Mirati之前，Faga先生于2016年5月至2019年12月期间担任星火治疗，Inc.的首席BINCE官，负责领导公司的公司战略、产品组合和新产品规划、患者倡导、BINCE开发、联盟管理、资产和项目管理以及企业传播职能。从2009年7月到2016年4月，Faga先生担任投资银行和咨询公司CenterView Partners的董事总经理，并担任CenterView的医疗保健咨询业务的创始成员。在加入CenterView之前，Faga先生曾在美林证券的医疗保健投资银行集团任职，并在PRTM担任生命科学实践部门的管理顾问。法加先生获得了康奈尔大学的工程学学士学位和宾夕法尼亚大学沃顿商学院的医疗保健管理硕士学位。
- Daniel Faga serves as First Tracks Biotherapeutics, Inc. President, Chief Executive Officer and a member of First Tracks Biotherapeutics, Inc. Board effective prior to the completion of the Spin Off. He currently serves as President and Chief Executive Officer and a member of the AnaptysBio, Inc. Board. Mr. Faga previously served as the Interim President and Chief Executive Officer of AnaptysBio, Inc. from March 2022 to August 2023. From January 2020 to November 2021, Mr. Faga served as Chief Operating Officer at Mirati Therapeutics, responsible for leading the company's corporate strategy, finance, legal and other business operations. Prior to joining Mirati, Mr. Faga served as the Chief Business Officer for Spark Therapeutics, Inc. from May 2016 through December 2019, where he was responsible for leading the company's corporate strategy, portfolio and new product planning, patient advocacy, business development, alliance management, asset & program management and corporate communications functions. From July 2009 until April 2016, Mr. Faga was a Managing Director at Centerview Partners, an investment banking and advisory firm, where he served as a founding member of Centerview's healthcare advisory practice. Prior to Centerview, Mr. Faga worked at Merrill Lynch in its healthcare investment banking group and as a management consultant in the Life Sciences Practice at PRTM. Mr. Faga earned a B.S. in Engineering from Cornell University and an M.B.A. in Health Care Management from The Wharton School at the University of Pennsylvania.
- Daniel Faga
Daniel Faga自2021年11月起担任董事会成员，并自2023年8月起担任AnaptysBio, Inc.总裁兼首席执行官。Faga先生此前曾于2022年3月至2023年8月担任AnaptysBio, Inc.的临时总裁兼首席执行官。2020年1月至2021年11月，Faga先生在Mirati Therapeutics担任首席运营官，负责领导公司的公司战略、财务、法律和其他业务运营。在加入Mirati Therapeutics之前，Faga先生于2016年5月至2019年12月期间担任星火治疗，Inc.的首席商务官，负责领导公司的公司战略、产品组合和新产品规划、患者宣传、业务发展、联盟管理、资产和项目管理以及企业传播职能。从2009年7月到2016年4月，Faga先生在投资银行和咨询公司CenterView Partners担任董事总经理，并担任CenterView的医疗保健咨询业务的创始成员。在加入CenterView之前，Faga先生曾在美林证券的医疗保健投资银行集团任职，并在PRTM担任生命科学实践部门的管理顾问。法加先生获得了康奈尔大学的工程学学士学位和宾夕法尼亚大学沃顿商学院的医疗保健管理硕士学位。AnaptysBio, Inc.董事会认为，Faga先生丰富的行业经验和高管经验为其提供了在AnaptysBio, Inc.董事会任职的资格和技能。
Daniel Faga has served as a member of Board since November 2021, and has served as Anaptysbio, Inc.'s President and Chief Executive Officer since August 2023. Mr. Faga previously served as Anaptysbio, Inc.'s Interim President and Chief Executive Officer from March 2022 to August 2023. From January 2020 to November 2021, Mr. Faga served as Chief Operating Officer at Mirati Therapeutics, responsible for leading the company's corporate strategy, finance, legal and other business operations. Prior to joining Mirati Therapeutics, Mr. Faga served as the Chief Business Officer for Spark Therapeutics, Inc. from May 2016 through December 2019, where he was responsible for leading the company's corporate strategy, portfolio and new product planning, patient advocacy, business development, alliance management, asset & program management and corporate communications functions. From July 2009 until April 2016, Mr. Faga was a Managing Director at Centerview Partners, an investment banking and advisory firm, where he served as a founding member of Centerview's healthcare advisory practice. Prior to Centerview, Mr. Faga worked at Merrill Lynch in its healthcare investment banking group and as a management consultant in the Life Sciences Practice at PRTM. Mr. Faga earned a B.S. in Engineering from Cornell University and an M.B.A. in Health Care Management from The Wharton School at the University of Pennsylvania. Anaptysbio, Inc.'s Board believes that Mr. Faga's extensive industry experience and executive experience provides him with the qualifications and skills to serve on Anaptysbio, Inc.'s Board.- Daniel Faga自2021年11月起担任董事会成员，并自2023年8月起担任AnaptysBio, Inc.总裁兼首席执行官。Faga先生此前曾于2022年3月至2023年8月担任AnaptysBio, Inc.的临时总裁兼首席执行官。2020年1月至2021年11月，Faga先生在Mirati Therapeutics担任首席运营官，负责领导公司的公司战略、财务、法律和其他业务运营。在加入Mirati Therapeutics之前，Faga先生于2016年5月至2019年12月期间担任星火治疗，Inc.的首席商务官，负责领导公司的公司战略、产品组合和新产品规划、患者宣传、业务发展、联盟管理、资产和项目管理以及企业传播职能。从2009年7月到2016年4月，Faga先生在投资银行和咨询公司CenterView Partners担任董事总经理，并担任CenterView的医疗保健咨询业务的创始成员。在加入CenterView之前，Faga先生曾在美林证券的医疗保健投资银行集团任职，并在PRTM担任生命科学实践部门的管理顾问。法加先生获得了康奈尔大学的工程学学士学位和宾夕法尼亚大学沃顿商学院的医疗保健管理硕士学位。AnaptysBio, Inc.董事会认为，Faga先生丰富的行业经验和高管经验为其提供了在AnaptysBio, Inc.董事会任职的资格和技能。
- Daniel Faga has served as a member of Board since November 2021, and has served as Anaptysbio, Inc.'s President and Chief Executive Officer since August 2023. Mr. Faga previously served as Anaptysbio, Inc.'s Interim President and Chief Executive Officer from March 2022 to August 2023. From January 2020 to November 2021, Mr. Faga served as Chief Operating Officer at Mirati Therapeutics, responsible for leading the company's corporate strategy, finance, legal and other business operations. Prior to joining Mirati Therapeutics, Mr. Faga served as the Chief Business Officer for Spark Therapeutics, Inc. from May 2016 through December 2019, where he was responsible for leading the company's corporate strategy, portfolio and new product planning, patient advocacy, business development, alliance management, asset & program management and corporate communications functions. From July 2009 until April 2016, Mr. Faga was a Managing Director at Centerview Partners, an investment banking and advisory firm, where he served as a founding member of Centerview's healthcare advisory practice. Prior to Centerview, Mr. Faga worked at Merrill Lynch in its healthcare investment banking group and as a management consultant in the Life Sciences Practice at PRTM. Mr. Faga earned a B.S. in Engineering from Cornell University and an M.B.A. in Health Care Management from The Wharton School at the University of Pennsylvania. Anaptysbio, Inc.'s Board believes that Mr. Faga's extensive industry experience and executive experience provides him with the qualifications and skills to serve on Anaptysbio, Inc.'s Board.